SLC38A4 Antibody

What is SLC38A4 and why is it important to study in research?

SLC38A4 (Solute Carrier Family 38 Member 4) is a protein found predominantly in liver tissue that functions as a transporter for both cationic and neutral amino acids. Its significance stems from several key biological aspects:

• Functions as a tumor suppressor in hepatocellular carcinoma (HCC)

• Mediates electrogenic symport of neutral amino acids and sodium ions with a preference for Ala, His, Cys, Asn, Ser, Gly, Val, Thr, Gln, and Met

• The transport mechanism varies by amino acid type - cationic amino acid transport is Na⁺ and pH independent, while neutral amino acid transport is Na⁺ and pH dependent

• Exhibits pH-dependent activity, with highest transport function between pH 7.5-8.5

• Low expression correlates with poor prognosis in HCC patients, suggesting diagnostic and prognostic value

Understanding SLC38A4 provides insights into fundamental amino acid metabolism, liver function, and potential therapeutic approaches for hepatocellular carcinoma.

What applications are SLC38A4 antibodies typically used for in research?

SLC38A4 antibodies are versatile tools employed across multiple research applications:

Research indicates positive Western blot detection has been confirmed in several cell lines including A549, Jurkat, and L02 cells, while positive IHC has been documented in human kidney tissue, human liver cancer tissue, and mouse liver tissue .

What tissues and species show the highest SLC38A4 expression?

Based on antibody validation studies and expression analyses:

Tissues with significant SLC38A4 expression:

• Liver (highest expression)

• Kidney

• Pancreatic α-cells (particularly in certain pathological conditions)

Species reactivity of SLC38A4 antibodies:

• Human (confirmed reactivity)

• Mouse (confirmed reactivity)

• Rat (confirmed reactivity)

• Additional predicted reactivity in dog, cow, pig, zebrafish, rabbit, guinea pig, and horse (based on sequence homology)

This cross-species reactivity makes SLC38A4 antibodies valuable for comparative studies across model organisms.

What are the optimal sample preparation methods for detecting SLC38A4 in Western blots?

Successful Western blot detection of SLC38A4 requires careful consideration of sample preparation:

Optimal Protocol:

• Lysis buffer selection: Use RIPA buffer with protease inhibitors for membrane protein extraction

• Sample homogenization: For liver tissue, mechanical disruption followed by gentle sonication yields best results

• Protein concentration: Load 20-50μg of total protein per lane

• Denaturation conditions: Heat samples at 95°C for 5 minutes in Laemmli buffer with DTT

• Gel percentage: Use 10% SDS-PAGE gels for optimal separation

• Transfer conditions: Wet transfer to PVDF membrane at 100V for 90 minutes

• Blocking solution: 5% non-fat milk in TBST (1 hour at room temperature)

• Primary antibody incubation: 1:500-1:1000 dilution overnight at 4°C

• Secondary antibody: Anti-rabbit HRP at 1:5000 for 1 hour at room temperature

• Expected molecular weight: ~61 kDa (may vary slightly between species)

Troubleshooting note: SLC38A4 is a membrane protein, so thorough solubilization is critical. If signal is weak, consider using stronger membrane disruption methods or alternative detergents like n-Dodecyl β-D-maltoside.

What antigen retrieval methods are recommended for SLC38A4 immunohistochemistry?

Successful IHC staining of SLC38A4 depends significantly on proper antigen retrieval:

Recommended Protocol:

• Primary retrieval method: TE buffer pH 9.0 (most effective for SLC38A4)

• Alternative method: Citrate buffer pH 6.0 (if TE buffer yields high background)

• Retrieval conditions: Heat-induced epitope retrieval (HIER) using pressure cooker or microwave

• Blocking: 3% hydrogen peroxide followed by 5% normal goat serum

• Primary antibody incubation: 1:20-1:200 dilution overnight at 4°C

• Detection system: DAB chromogen with ABC or polymer-based detection system

• Counterstain: Hematoxylin (light counterstaining recommended)

Optimization considerations:

• For formalin-fixed paraffin-embedded (FFPE) liver tissues, longer antigen retrieval times (15-20 minutes) often improve staining

• Fresh frozen sections may require shorter antigen retrieval or fixation optimization

• Background staining can be reduced by titrating antibody concentration and optimizing washing steps

How can I ensure specificity when using SLC38A4 antibodies?

Confirming antibody specificity is critical for reliable SLC38A4 research:

Recommended validation approaches:

Research example: Studies have validated SLC38A4 antibody specificity through stable knockdown using multiple shRNAs targeting different sites, demonstrating consistent effects on cellular proliferation, stemness, apoptosis, and migration, confirming the specificity of the antibody and the observed phenotypes .

How can SLC38A4 antibodies be used to investigate its role in hepatocellular carcinoma?

SLC38A4 has been identified as a tumor suppressor in HCC, making antibody-based detection crucial for research:

Research Applications:

Experimental design suggestion: Combine SLC38A4 IHC with tissue microarrays containing matched primary HCC, adjacent non-tumor tissue, and metastatic lesions to establish expression patterns across disease progression.

What approaches can resolve contradictory findings when studying SLC38A4 in different tissues?

Researchers may encounter contradictory results when studying SLC38A4 across different contexts:

Resolution strategies:

• Tissue-specific expression patterns:

  • SLC38A4 is predominantly expressed in liver , but also detected in kidney and pancreatic α-cells

  • Use transcriptomic databases (e.g., GTEx, Human Protein Atlas) alongside antibody validation to confirm expected expression

• Isoform-specific detection:

  • Verify which SLC38A4 isoform your antibody detects (check epitope information)

  • Western blot analysis may reveal tissue-specific isoforms or post-translational modifications

• Context-dependent regulation:

  • SLC38A4 expression increases in pancreatic α-cells after glucagon receptor blocking antibody treatment

  • Use multiple antibodies targeting different epitopes to verify context-dependent regulation

• Experimental standardization:

  • Standardize fixation, antigen retrieval, and staining protocols across tissues

  • Include positive and negative controls specific to each tissue context

Case study example: While SLC38A4 functions as a tumor suppressor in HCC , increased expression was observed in pancreatic α-cells in patients with glucagon cell hyperplasia and neoplasia (GCHN) . This apparent contradiction can be resolved by understanding tissue-specific functions and regulatory mechanisms.

How can SLC38A4 antibodies be used to study its regulation by the mTOR pathway?

Evidence suggests mechanistic target of rapamycin (mTOR) pathway involvement in SLC38A4 regulation:

Experimental approaches:

• Pharmacological modulation:

  • Treat cell models with rapamycin (mTOR inhibitor) and measure SLC38A4 expression by Western blot and qRT-PCR

  • Results from studies show that increased SLC38A4 expression and associated α-cell proliferation is dependent on mTOR pathway

• Pathway analysis:

  • Use co-immunoprecipitation with SLC38A4 antibodies followed by mass spectrometry to identify interacting proteins in the mTOR pathway

  • Perform Western blot analysis for mTOR pathway components (mTOR, p70S6K, 4E-BP1) in combination with SLC38A4

• In vivo validation:

  • Examine SLC38A4 expression in tissues from rapamycin-treated animal models using IHC and Western blot

  • Correlate with phosphorylation status of mTOR pathway components

Experimental design table:

What are the most common causes of false negative results when using SLC38A4 antibodies?

Researchers may encounter false negatives when detecting SLC38A4:

Common causes and solutions:

• Inadequate protein extraction:

  • SLC38A4 is a multi-pass membrane protein requiring effective membrane disruption

  • Solution: Use stronger detergents (e.g., SDS, Triton X-100) in extraction buffers

• Inappropriate antibody dilution:

  • Recommended dilutions range from 1:20-1:200 for IHC and 1:500-1:1000 for WB

  • Solution: Perform antibody titration to determine optimal concentration

• Insufficient antigen retrieval:

  • TE buffer pH 9.0 is recommended as primary retrieval method

  • Solution: Extend retrieval time or test alternative buffers (citrate buffer pH 6.0)

• Sample degradation:

  • Protein degradation during extraction or storage

  • Solution: Use fresh samples, maintain cold chain, add protease inhibitors

• Epitope masking:

  • Post-translational modifications may mask the epitope

  • Solution: Try antibodies targeting different epitopes (N-terminal vs. C-terminal)

• Low expression levels:

  • SLC38A4 expression varies by tissue and pathological state

  • Solution: Use more sensitive detection methods (amplification systems for IHC, chemiluminescent substrates for WB)

Methodological note: Multiple studies confirm successful detection in liver samples, with antibodies showing expected ~61 kDa bands in Western blots from liver cell lines .

How can co-localization studies be optimized when using SLC38A4 antibodies?

Co-localization studies provide valuable insights into SLC38A4 function:

Optimization strategies:

• Antibody compatibility:

  • Ensure primary antibodies are raised in different species to avoid cross-reactivity

  • For SLC38A4, rabbit polyclonal antibodies are common , so pair with mouse antibodies for co-markers

• Fixation optimization:

  • Test multiple fixatives (4% PFA, methanol, acetone) as membrane proteins may require specific conditions

  • Mild permeabilization (0.1% Triton X-100) typically works well for SLC38A4

• Subcellular marker selection:

  • Use established markers for plasma membrane (Na⁺/K⁺-ATPase), early endosomes (EEA1), or other relevant compartments

  • Wnt/β-catenin pathway components are relevant co-markers based on functional studies

• Imaging parameters:

  • Use sequential scanning to minimize bleed-through

  • Employ deconvolution or super-resolution techniques for membrane protein localization

• Quantification approaches:

  • Calculate Pearson's correlation coefficient or Manders' overlap coefficient

  • Analyze at least 30-50 cells across multiple fields for statistical significance

Technical note: When studying co-localization of SLC38A4 with Wnt/β-catenin pathway components, use β-catenin antibodies to visualize nuclear translocation along with SLC38A4 membrane localization to correlate pathway activation with SLC38A4 expression patterns .

What controls should be included when performing immunofluorescence with SLC38A4 antibodies?

Proper controls are essential for reliable immunofluorescence results:

Essential controls:

Advanced consideration: When studying SLC38A4 in HCC, include both tumor and adjacent non-tumor tissue on the same slide processed identically to directly compare expression patterns, as studies show significant differential expression between these tissues .

How should contradictory findings about SLC38A4 expression in cancer be interpreted?

Contradictory findings regarding SLC38A4 in cancer contexts require careful interpretation:

Interpretive framework:

• Tissue-specific differences:

  • SLC38A4 functions as a tumor suppressor in HCC with downregulation in tumor tissues

  • Expression patterns may differ in other cancer types based on tissue-specific regulation

• Methodological considerations:

  • Western blot quantification should be normalized to appropriate loading controls

  • IHC scoring should account for both staining intensity and percentage of positive cells

  • Compare antibodies targeting different epitopes to confirm findings

• Contextual interpretation:

  • Consider microenvironmental factors (hypoxia, nutrient availability) that may affect amino acid transporter expression

  • Examine SLC38A4 expression in context of related transporters (SLC38 family members)

• Genetic and epigenetic regulation:

  • DNA hypermethylation contributes to SLC38A4 downregulation in HCC

  • Verify methylation status alongside protein expression studies

Analytical approach: When encountering contradictory findings, perform meta-analysis of available data across multiple studies, stratifying by cancer type, methodological approach, and specific antibodies used for detection.

What quantitative approaches are most appropriate for measuring SLC38A4 levels in IHC studies?

Quantitative analysis of SLC38A4 IHC requires standardized approaches:

Recommended methods:

• H-score calculation:

  • Formula: H-score = Σ(Pi × i) where i = intensity (0-3) and Pi = percentage of cells (0-100%)

  • Range: 0-300

  • Advantage: Accounts for both staining intensity and proportion of positive cells

• Automated image analysis:

  • Use digital pathology systems with algorithms for membrane protein quantification

  • Parameters: DAB intensity, membrane completeness, percentage positive cells

  • Advantage: Reduces inter-observer variability

• Multiplex IHC quantification:

  • Combine SLC38A4 staining with cell type markers and outcome indicators

  • Use multispectral imaging systems for colocalization analysis

  • Advantage: Provides cellular context for expression patterns

Scoring system example from published studies:

Research has shown that significantly weaker staining density of SLC38A4 in HCC tissues compared with paired nontumor liver tissues correlates with clinical outcomes .